P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
The malignant clone and the bone-marrow environment.
TL;DR: Delineating the mechanisms and sequelae of the reciprocal relationship between the MM cell clone, distinct BM extracellular matrix proteins, and accessory cell compartments may provide the basis for new effective therapeutic strategies to re-establish BM homeostasis and thereby improve MM patient outcome.
Journal ArticleDOI
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
Hervé Avet-Loiseau,Nizar J. Bahlis,Wee Joo Chng,Tamás Masszi,Luisa Viterbo,Ludek Pour,Peter Ganly,Antonio Palumbo,Michele Cavo,Christian Langer,Andrzej Pluta,Arnon Nagler,Shaji Kumar,Dina Ben-Yehuda,S. Vincent Rajkumar,Jesús F. San-Miguel,Deborah Berg,Jianchang Lin,Helgi van de Velde,Dixie Lee Esseltine,Alessandra Di Bacco,Philippe Moreau,Paul G. Richardson +22 more
TL;DR: IRd demonstrated substantial benefit compared with placebo-Rd in relapsed and/or refractory MM (RRMM) patients with high-risk and standard-risk cytogenetics, and improves the poor PFS associated withHigh- risk cytogenetic abnormalities.
Journal Article
Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.
Masaharu Akiyama,Teru Hideshima,Masood A. Shammas,Toshiaki Hayashi,Makoto Hamasaki,Yu-Tzu Tai,Paul G. Richardson,Sergei M. Gryaznov,Nikhil C. Munshi,Kenneth C. Anderson +9 more
TL;DR: The molecular sequelae of NP oligonucleotide (GRN163) against human telomersase RNA component as a telomerase inhibitor are identified and the rationale for the development of telomerases-targeted therapies to improve patient outcome in MM is provided.
Journal ArticleDOI
Promising therapies in multiple myeloma
TL;DR: Progress in medical research has enhanced understanding of tumor biology, delineated genetic and molecular mechanisms of tumor growth and survival, and defined the impact of the microenvironment in cancer pathogenesis, resulting in cancers deemed rapidly fatal only a few.
Journal ArticleDOI
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant
Tarek H. Mouhieddine,Tarek H. Mouhieddine,Adam S. Sperling,Robert A. Redd,Jihye Park,Jihye Park,Matthew Leventhal,Christopher J. Gibson,Salomon Manier,Salomon Manier,Salomon Manier,Amin Nassar,Amin Nassar,Marzia Capelletti,Daisy Huynh,Mark Bustoros,Mark Bustoros,Romanos Sklavenitis-Pistofidis,Romanos Sklavenitis-Pistofidis,Sabrin Tahri,Sabrin Tahri,Kalvis Hornburg,Henry Dumke,Muhieddine M. Itani,Cody J. Boehner,Chia Jen Liu,Saud H. AlDubayan,Brendan Reardon,Eliezer M. Van Allen,Jonathan J Keats,Chip Stewart,Shaadi Mehr,Daniel Auclair,Robert L. Schlossman,Nikhil C. Munshi,Kenneth C. Anderson,David P. Steensma,Jacob P. Laubach,Paul G. Richardson,Jerome Ritz,Benjamin L. Ebert,Benjamin L. Ebert,Robert J. Soiffer,Lorenzo Trippa,Gad Getz,Gad Getz,Donna Neuberg,Irene M. Ghobrial,Irene M. Ghobrial +48 more
TL;DR: The authors show that the presence of clonal haematopoiesis of indeterminate potential (CHIP) at time of ASCT is associated with adverse outcomes in MM patients.